sameAs
P3781
Absorption and Systemic Study of AN2690 in Patients With Moderate to Severe Onychomycosis (ADME I)Efficacy and Safety of AN2690 Topical Solution to Treat Onychomycosis of the ToenailAn Evaluation of the Safety and Pharmacokinetics of Tavaborole Topical Solution for the Treatment of Fungal Disease of the Toenail in Children and AdolescentsEfficacy and Safety Evaluation of AN2690 Topical Solution to Treat Onychomycosis of the ToenailStudy of Different Doses of a Novel Treatment for OnychomycosisAbsorption and Systemic Study of AN2690 in Patients With Moderate to Severe Onychomycosis (ADME II)Safety and Efficacy Study of Subjects With Onychomycosis of the Great ToenailSafety and Efficacy Evaluation of Topically Applied AN2690 Solutions for Subjects With OnychomycosisSafety and Efficacy Study of Subjects With Onychomycosis of the Great Toenail (2007-03-31)Cumulative Irritation Test (2007-01-22)Study of Different Doses of a Novel Treatment for Onychomycosis (2006-02-28)
P4844
An antifungal agent inhibits an aminoacyl-tRNA synthetase by trapping tRNA in the editing siteCrystal structures of the human and fungal cytosolic Leucyl-tRNA synthetase editing domains: A structural basis for the rational design of antifungal benzoxaborolestRNA-dependent pre-transfer editing by prokaryotic leucyl-tRNA synthetase.Characterization of benzoxaborole-based antifungal resistance mutations demonstrates that editing depends on electrostatic stabilization of the leucyl-tRNA synthetase editing cap.New therapeutic options for onychomycosis.5-Fluoro-1,3-dihydro-2,1-benzoxaborol-1-olCurrent and emerging options in the treatment of onychomycosis.AN-2690, a novel antifungal for the topical treatment of onychomycosis.Investigational drugs for onychomycosis.From the Test Tube to the Treatment Room: Fundamentals of Boron-containing Compounds and their Relevance to Dermatology.Post-transfer editing by a eukaryotic leucyl-tRNA synthetase resistant to the broad-spectrum drug AN2690.An assessment of the genetic toxicology of novel boron-containing therapeutic agents.In Vitro penetration of a novel oxaborole antifungal (AN2690) into the human nail plate.Discovery of a new boron-containing antifungal agent, 5-fluoro-1,3-dihydro-1-hydroxy-2,1- benzoxaborole (AN2690), for the potential treatment of onychomycosis.
P921
Q61865085-9730F577-436A-4EE8-A89C-6E549969EA16Q63337594-64B44A40-70B5-497D-A65E-BC720AA30F34Q63404614-868B65C2-D657-4ECF-99DC-52600244BA87Q63815885-7C2D7766-515F-4236-8247-26885BF2D10EQ64046078-9B484A8F-3B98-4652-BC45-B27A9344511DQ64046110-1B2976C1-C3E0-4AD8-B7FB-038F63340B88Q64046123-F8802D2C-6716-4DD7-8D95-12895E849DB4Q64719715-6AC8C115-B567-45B1-A732-05AF740A094FQ86171011-EAA45872-DD6A-42C3-BB0A-3C0C7FC466F8Q86175765-191C37D4-1E08-49A7-87F0-B4EB8E8AC850Q86175793-F937B089-89A4-48F5-965A-EB5C3596B97E
P4844
Q27646383-49E6C5AD-EC63-4A62-B8EE-5D748F5CF746Q27655423-9F7754D6-5BD3-4EE6-9660-B9FEB5B04F9CQ33661496-068AB5AA-2037-439C-9F8D-4201ED6EC24BQ34209500-F2AFA957-3FC9-4883-853D-5F6028D8C6A5Q34245375-C72D9FC6-80B7-437D-850A-1A1027F90BC4Q34637111-4F18ED41-9B18-46C2-8904-325DBFBE4007Q35025640-A3CA3881-7512-4463-91EB-9913C9C60C0EQ36898837-AA275789-E473-40C3-BB07-A5C5E16B4054Q38144164-0342FBD1-4A3D-46EA-A62D-4B745B0A6F2CQ38191916-F09DDD73-F41D-43A1-B735-3E0C983DAF01Q43015002-D76B3737-8FEE-4E20-B310-8F86F19CF62FQ46003426-6F6EBA91-C3E8-423D-BD31-22301659BFE9Q46247135-53A632A2-3483-411B-9C0D-8B99EE9AA85FQ46735564-20E07D3B-6877-4737-A4ED-BE6E9AA5B2C1
P921
description
chemesch Verbindung
@lb
chemical compound
@en
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de
chemische Verbindung
@de-ch
chemische verbinding
@nl
name
Tavaborole
@vi
tavaborole
@en
type
label
Tavaborole
@vi
tavaborole
@en
altLabel
5-Fluoro-1,3-dihydro-1-hydroxy-2,1-benzoxaborole
@en
5-Fluoro-2,1-benzoxaborol-1(3H)-ol
@en
AN 2690
@en
AN-2690
@en
AN2690
@en
Tavaborole
@en
prefLabel
Tavaborole
@vi
tavaborole
@en
P486
P592
P6366
P661
P662
P665
P683
P117
P1579
P2067
152.044488
P2115
N0000191084
P2275
Tavaborole
@en